Standardization of terminology of virological response in the treatment of chronic hepatitis C: Panel recommendations

I. M. Jacobson, F. Poordad, R. S. Brown, P. Y. Kwo, K. R. Reddy, E. Schiff

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Summary. The treatment paradigm for hepatitis C virus (HCV) infection is at a critical point in its evolution. The addition of a protease inhibitor to peginterferon plus ribavirin has become the new standard-of-care treatment for most patients. Data from clinical trials of new antivirals have been difficult to interpret and compare, partly because of heterogeneity in trial design, and partly because of inconsistencies in terminology used to define viral responses and the populations evaluated. Present definitions of viral responses for treatment with peginterferon and ribavirin are insufficient for novel treatment paradigms. Further, categorization of prior patient treatment experience in clinical trials, particularly of nonresponders to prior therapy, is inconsistent. Existing terms and definitions must be updated, standardized and/or redefined for easier interpretation of data and effective communication among clinicians. A panel of experts in HCV infection treatment met on 3 December 2009. Goals of the panel were to evaluate terms and definitions used traditionally in treatment with peginterferon and ribavirin, to refine and clarify definitions of existing terms that have varying meanings and to propose new terms and definitions appropriate for novel treatment paradigms emerging with development of new agents. A number of recommendations were accepted unanimously by the panel. Adoption of these terms would improve communication among investigators, enhance comparability among clinical trials, facilitate development of therapeutic guidelines and provide a standardized terminology for use in clinical practice.

Original languageEnglish
Pages (from-to)236-243
Number of pages8
JournalJournal of Viral Hepatitis
Volume19
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Chronic Hepatitis C
Terminology
Ribavirin
Therapeutics
Clinical Trials
Virus Diseases
Hepacivirus
Communication
Standard of Care
Protease Inhibitors
Antiviral Agents
Research Personnel
Guidelines

Keywords

  • direct-acting antiviral
  • genotype 1
  • lead-in dosing
  • protease inhibitor

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Standardization of terminology of virological response in the treatment of chronic hepatitis C : Panel recommendations. / Jacobson, I. M.; Poordad, F.; Brown, R. S.; Kwo, P. Y.; Reddy, K. R.; Schiff, E.

In: Journal of Viral Hepatitis, Vol. 19, No. 4, 04.2012, p. 236-243.

Research output: Contribution to journalArticle

Jacobson, I. M. ; Poordad, F. ; Brown, R. S. ; Kwo, P. Y. ; Reddy, K. R. ; Schiff, E. / Standardization of terminology of virological response in the treatment of chronic hepatitis C : Panel recommendations. In: Journal of Viral Hepatitis. 2012 ; Vol. 19, No. 4. pp. 236-243.
@article{2e13d01b6fce4441a021a0d8dc2111f4,
title = "Standardization of terminology of virological response in the treatment of chronic hepatitis C: Panel recommendations",
abstract = "Summary. The treatment paradigm for hepatitis C virus (HCV) infection is at a critical point in its evolution. The addition of a protease inhibitor to peginterferon plus ribavirin has become the new standard-of-care treatment for most patients. Data from clinical trials of new antivirals have been difficult to interpret and compare, partly because of heterogeneity in trial design, and partly because of inconsistencies in terminology used to define viral responses and the populations evaluated. Present definitions of viral responses for treatment with peginterferon and ribavirin are insufficient for novel treatment paradigms. Further, categorization of prior patient treatment experience in clinical trials, particularly of nonresponders to prior therapy, is inconsistent. Existing terms and definitions must be updated, standardized and/or redefined for easier interpretation of data and effective communication among clinicians. A panel of experts in HCV infection treatment met on 3 December 2009. Goals of the panel were to evaluate terms and definitions used traditionally in treatment with peginterferon and ribavirin, to refine and clarify definitions of existing terms that have varying meanings and to propose new terms and definitions appropriate for novel treatment paradigms emerging with development of new agents. A number of recommendations were accepted unanimously by the panel. Adoption of these terms would improve communication among investigators, enhance comparability among clinical trials, facilitate development of therapeutic guidelines and provide a standardized terminology for use in clinical practice.",
keywords = "direct-acting antiviral, genotype 1, lead-in dosing, protease inhibitor",
author = "Jacobson, {I. M.} and F. Poordad and Brown, {R. S.} and Kwo, {P. Y.} and Reddy, {K. R.} and E. Schiff",
year = "2012",
month = "4",
doi = "10.1111/j.1365-2893.2011.01552.x",
language = "English",
volume = "19",
pages = "236--243",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Standardization of terminology of virological response in the treatment of chronic hepatitis C

T2 - Panel recommendations

AU - Jacobson, I. M.

AU - Poordad, F.

AU - Brown, R. S.

AU - Kwo, P. Y.

AU - Reddy, K. R.

AU - Schiff, E.

PY - 2012/4

Y1 - 2012/4

N2 - Summary. The treatment paradigm for hepatitis C virus (HCV) infection is at a critical point in its evolution. The addition of a protease inhibitor to peginterferon plus ribavirin has become the new standard-of-care treatment for most patients. Data from clinical trials of new antivirals have been difficult to interpret and compare, partly because of heterogeneity in trial design, and partly because of inconsistencies in terminology used to define viral responses and the populations evaluated. Present definitions of viral responses for treatment with peginterferon and ribavirin are insufficient for novel treatment paradigms. Further, categorization of prior patient treatment experience in clinical trials, particularly of nonresponders to prior therapy, is inconsistent. Existing terms and definitions must be updated, standardized and/or redefined for easier interpretation of data and effective communication among clinicians. A panel of experts in HCV infection treatment met on 3 December 2009. Goals of the panel were to evaluate terms and definitions used traditionally in treatment with peginterferon and ribavirin, to refine and clarify definitions of existing terms that have varying meanings and to propose new terms and definitions appropriate for novel treatment paradigms emerging with development of new agents. A number of recommendations were accepted unanimously by the panel. Adoption of these terms would improve communication among investigators, enhance comparability among clinical trials, facilitate development of therapeutic guidelines and provide a standardized terminology for use in clinical practice.

AB - Summary. The treatment paradigm for hepatitis C virus (HCV) infection is at a critical point in its evolution. The addition of a protease inhibitor to peginterferon plus ribavirin has become the new standard-of-care treatment for most patients. Data from clinical trials of new antivirals have been difficult to interpret and compare, partly because of heterogeneity in trial design, and partly because of inconsistencies in terminology used to define viral responses and the populations evaluated. Present definitions of viral responses for treatment with peginterferon and ribavirin are insufficient for novel treatment paradigms. Further, categorization of prior patient treatment experience in clinical trials, particularly of nonresponders to prior therapy, is inconsistent. Existing terms and definitions must be updated, standardized and/or redefined for easier interpretation of data and effective communication among clinicians. A panel of experts in HCV infection treatment met on 3 December 2009. Goals of the panel were to evaluate terms and definitions used traditionally in treatment with peginterferon and ribavirin, to refine and clarify definitions of existing terms that have varying meanings and to propose new terms and definitions appropriate for novel treatment paradigms emerging with development of new agents. A number of recommendations were accepted unanimously by the panel. Adoption of these terms would improve communication among investigators, enhance comparability among clinical trials, facilitate development of therapeutic guidelines and provide a standardized terminology for use in clinical practice.

KW - direct-acting antiviral

KW - genotype 1

KW - lead-in dosing

KW - protease inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84858295907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858295907&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2893.2011.01552.x

DO - 10.1111/j.1365-2893.2011.01552.x

M3 - Article

C2 - 22404721

AN - SCOPUS:84858295907

VL - 19

SP - 236

EP - 243

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 4

ER -